Cilastatin/imipenem/relebactam

Drug Profile

Cilastatin/imipenem/relebactam

Alternative Names: Cilastatin/relebactam/imipenem; IMI/REL; Imipenem/cilastatin/relebactam; Imipenem/relebactam/cilastatin; MK 7655; MK-7655 + cilastatin/imipenem; MK-7655 + imipenem/cilastatin; MK-7655A; Relebactam + imepenem/cilastatin; Relebactam/cilastatin/imipenem; Relebactam/imipenem/cilastatin

Latest Information Update: 04 Jul 2016

Price : $50

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antibacterials; Azabicyclo compounds; Carbapenems; Cyclopropanes; Piperidines; Small molecules; Thienamycins
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors; Exopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Bacterial infections; Pneumonia
  • New Molecular Entity No

Highest Development Phases

  • Phase III Bacterial infections; Pneumonia

Most Recent Events

  • 20 Jun 2016 Interim efficacy and adverse events data from a phase II trial in bacterial infections released by Merck
  • 24 Dec 2015 Phase-III clinical trials in Pneumonia in South Korea (IV) (NCT02493764)
  • 01 Nov 2015 Phase-III clinical trials in Pneumonia in Latvia, Estonia, Germany and Russia (IV) (NCT02493764)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top